NCT02864498View on ClinicalTrials.gov

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Atopic Dermatitis
Interventions
DRUG

DS107

DRUG

Placebo

Trial Locations (2)

Unknown

DS Biopharma Site, Philadelphia

DS Biopharma Site, Cape Town

Sponsors

Lead Sponsor

DS Biopharma
All Listed Sponsors
lead

DS Biopharma

INDUSTRY